Trial Profile
A Phase II, Open-Label, Non-Randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Kaposi's sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 15 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2009 New trial record